Educational research only—not investment advice or a recommendation. Scores and estimates may use delayed, incomplete, restated, or corrected market and filing data. Independently verify information before making an investment decision.
Price updated todayFinancials updated Oct 19, 2026
Explore stock sections · swipe left or right
SNN · Price history
Price at last available close
$30.12
+$3.17 (+11.76%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
How they make money
Smith+Nephew operates through a business model focused on product development and acquisition, utilizing an R&D model to drive innovation in medical technologies. The company generates revenue by commercializing these products globally, supported by a network of medical education programs that facilitate the safe and effective use of its surgical and wound management devices.
Products & services
The company provides medical devices and technologies across three main franchises: Orthopaedics (hip and knee implants), Sports Medicine & ENT (soft tissue repair instruments), and Advanced Wound Management (wound care products).
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Orthopaedics, Sports Medicine and Ear Nose and ThroatUSD 4.37B70.9%
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
The company does not disclose specific major customers or significant customer concentration in its 2025 Annual Report.
Suppliers, materials & equipment
Contract manufacturers — The company utilizes various third-party contract manufacturers to support its global manufacturing and supply chain operations.Source
Competitors
Stryker Corporation — Competes in the orthopaedic and medical device markets.Source
Zimmer Biomet — Competes in the orthopaedic reconstruction and sports medicine markets.Source
DePuy Synthes (Johnson & Johnson) — Competes in orthopaedic and surgical device segments.Source
Overall investment score · Quality, value, risk and opportunity
60
Fair
PoorElite
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
72
Strong
Financial Strength
67
Business Quality / Moat
59
Management
91
Growth Quality
82
Risk / Durability
73
Great Company · Attractive Price
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
77
Fair
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
71/100
Building Historical Record
Model Score 71/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is mixed across its combined quality, valuation and risk inputs. Review the category scores to identify what is helping or hurting the result.
At today’s price, the WSS valuation framework currently reads as relatively attractive.
The model outlook is currently positive.
What we like
•Balance-sheet / debt profile scores strongly
•Valuation scores attractively
•Recent buyback activity is present
What to watch
•Revenue fundamentals are weak
•Asset quality is a weaker factor
Company-specific research
Questions worth answering for SNN
Research inputs 100% complete
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
•Can SNN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
•Is SNN's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
•Is SNN's debt load manageable relative to cash generation, interest costs and upcoming maturities?
•Is SNN's valuation discount tied to a temporary concern or to a longer-term business risk?
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
Volatility = How violently is it moving?
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for SNN
Detected from reported data — verify before acting.
Dividend history reported
The provider reports a dividend yield. Confirm the latest declaration before treating it as a current payment.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total calls
0% Bullish (0) 0% Bearish (0)
No personal call yet on SNN.
Potential upside factors
+Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
+Innovation pipeline and R&D model.
+Global manufacturing and supply chain resilience.
+Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
−Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
−Regulatory and compliance risks.
−Supply chain disruptions.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdown
Wall Street Score
Fair60/ 100
Weak (0–50)Fair (51–71)Strong (72+)
Debt
Strong
74
Debt Cost4.2%
Debt Reduction YoY-0.2%
Debt / Equity0.63x
Tap for breakdown →
Revenue
Weak
48
Revenue YoY98.6%
Revenue CAGR5.4%
Net Margin9.2%
Tap for breakdown →
Asset
Poor
37
Asset Growth YoY1.0%
Liquidation/Share$11.87
Net Assets/MCap0.60x
Tap for breakdown →
Capital
Fair
64
Earnings Yield9.3%
Buyback Yield1.4%
Debt Cost4.2%
Tap for breakdown →
Management
Elite
91
ROIC7.8%
ROE21.7%
ROA10.2%
Tap for breakdown →
Moat
Fair
59
EPS Growth22.0%
FCF/Share Growth31.6%
Rev/Share Growth5.0%
Tap for breakdown →
Valuation
Elite
97
Intrinsic Value$52.70
Value Reference$31.62
MOS42.8%
Tap for breakdown →
Buffett
Fair
66
Revenue48
Moat59
Valuation97
Tap for breakdown →
MOS
Elite
100
MOS %42.8%
Value Reference$31.62
Deep Discount Reference$21.08
Tap for breakdown →
Financial
Poor
30
Interest Coverage5.6x
ROIC7.8%
FCF Yield7.1%
Tap for breakdown →
Master
Fair
53
Financial30
Valuation97
Debt74
Tap for breakdown →
Resilience
Fair
56
Survival Years0.3 yrs
Current Ratio2.57x
FCF Margin13.8%
Tap for breakdown →
Was this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
YesNot yetDismiss
Score Changes
3 historical score records available
Previous Score
60
Oct 1, 2026
Change
-0.6
points
Current Score
60
Oct 19, 2026
Category Changes
Revenue-1.6
Debt0
Assets-1.7
Capital-4.0
Management0
Moat0
Valuation0
Buffett-0.6
SNN decreased 0.6 points because Capital declined by 4 points.
Negative Contributors
− Capital declined by 4 points
Projected Score
Projected Score
61
Projected Change
+1.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 1.6 points. This is a projected estimate, not the official WallStreetScore.
Monetary values in USD. Share counts in raw units.
Income StatementBalance SheetCash Flow
AnnualQuarterlyTTM + Annual
All rows
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
Line Item
TTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
$12.24B
$6.16B
$5.81B
$5.55B
····
····
····
····
····
····
····
Cost of Revenue
$3.74B
$1.96B
$1.73B
$1.65B
····
····
····
····
····
····
····
Gross Profit
$8.51B
$4.21B
$4.08B
$3.90B
····
····
····
····
····
····
····
Research & Development
$702.0M
$346.0M
$343.0M
$339.0M
····
····
····
····
····
····
····
SG&A Expenses
$6.03B
$3.04B
$2.90B
$2.83B
····
····
····
····
····
····
····
Operating Expenses
$6.94B
$3.41B
$3.42B
$3.47B
····
····
····
····
····
····
····
EBITDA
$3.13B
$1.45B
$1.44B
$1.27B
····
····
····
····
····
····
····
Operating Income
$1.57B
$794.0M
$657.0M
$425.0M
····
····
····
····
····
····
····
Interest Expense
$302.5M
$141.3M
$150.1M
$132.5M
····
····
····
····
····
····
····
Income Before Tax
$1.40B
$779.0M
$498.0M
$290.0M
····
····
····
····
····
····
····
Income Tax Expense
$278.0M
$154.0M
$86.0M
$27.0M
····
····
····
····
····
····
····
Net Income
$1.13B
$625.0M
$412.0M
$263.0M
····
····
····
····
····
····
····
Basic EPS
$2.64
$1.46
$0.94
$1.20
····
····
····
····
····
····
····
Basic Shares
430M
433M
438M
218M
····
····
····
····
····
····
····
Diluted Shares
430M
436M
438M
218M
····
····
····
····
····
····
····
Upgrade to Premium for up to 10 annual periods, where available.
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
Cash position grew
What Weakened
Margins contracted
Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels. Pressure indicators included debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 4.6%. EPS increased 2.9%. Cash increased 11.6%. Total debt increased 9.7%. Net income margin declined by 0.1 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Upgrade to Premium to unlock all earnings history.View plans
Government disclosed trading activity is available on the Smart Money directory. Filings may be delayed and may not represent complete current holdings.
Dividend HistoryShare
Dividend History
A dividend is reported, but detailed payment history is temporarily unavailable or awaiting refresh.
Predictions & Historical PerformanceShare
Conservative Projected Values
3 Years
$———.——
Premium
5 Years
$———.——
Premium
10 Years
$———.——
Premium
Conservative Projection Rate
——%
Premium
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.